Methods for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA
AssigneeThe Regents of the University of California
InventorsLiang You, Biao He, Zhidong Xu, David Jablons
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that overexpress Wnt2. The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such as a Frizzled receptor.
Claims34
A method of inhibiting proliferation of a cell that overexpresses a Wnt2, comprising contacting the cell with an amount of agent that inhibits Wnt2 signaling effective to inhibit proliferation of the cell.
A method of inducing apoptosis of a cell that overexpresses a Wnt2, comprising contacting the cell with an amount of an agent that inhibits Wnt2 signaling effective to induce apoptosis of the cell.
A method of inhibiting Wnt2 signaling in a cell, comprising contacting a cell that overexpresses a Wnt2 with an amount of an anti-Wnt2 antibody effective to inhibit Wnt2 signaling.
A method of treating a disease associated with Wnt2 signaling, comprising administering to a subject in need of such treatment an amount of an agent that inhibits Wnt2 signaling effective to treat the disease.
A method of treating cancer that overexpresses Wnt2, comprising administering to a subject an amount of an anti-Wnt2 antibody effective to treat the cancer.
A pharmaceutical composition comprising an anti-Wnt2 antibody and a pharmaceutically acceptable excipient, carrier, and/or diluent.
A monoclonal anti-Wnt2 antibody that specifically binds a polypeptide comprising an amino acid sequence that corresponds to amino acid residues 49-63 of human Wnt2.
Dependencies are inferred from the claim text.